To determine whether I23LI, 133H1, and [6'4Cjglucose provide an equivalent assessment of glucose turnover in insulin-dependent diabetes mellitus (IDDM) and nondiabetic man, glucose utilization rates were measured using a simultaneous infusion of these isotopes before and during hyperinsulinemic euglycemic clamps. In the nondiabetic subjects, glucose turnover rates determined with [614Cjglucose during insulin infusion were lower (P < 0.02) than those determined with [23Hjglucose and higher (P < 0.01) than those determined with 133Higlucose. In IDDM, glucose turnover rates measured with 1614Cjglucose during insulin infusion were lower (P < 0.05) than those determined with [23Hjglucose, but were not different from those determined with 133Hhglucose.
Introduction
Isotope dilution techniques are used extensively in clinical research to measure glucose turnover in diabetic and nondiabetic man. The ideal tracer for these measurements should both accurately reflect the pattern of nonradioactive glucose metabolism and not require complex processing. Although early studies in animals generally used ['4C ]-labeled glucose as a tracer (1, 2) , in recent years, glucose labeled with tritium has become the isotope most commonly used in clinical research. Use of tritiated glucose does not require correction for reincorporation of radioactivity back into the glucose molecule due to Cori cycle activity, whereas ['4C]glucose does (3, 4) . Glucose labeled with tritium in the second or third position has the additional advantage that samples do not have to be processed to remove radioactive three-carbon fragments as does glucose labeled with tritium in the sixth position (3, 5) . [33H] Glucose has gained wide acceptance in human studies after the demonstration in animals that results obtained with this isotope are comparable to those obtained with ['4C ]glucose corrected for Cori cycle activity (3, 5) . Whether this relationship applies to postabsorptive Receivedfor publication 11 October 1985 and in revisedform 17 June 1986. humans and whether it holds under conditions ofinsulin-induced changes in glucose utilization rates is unknown.
Use of [33H] glucose has several theoretical disadvantages.
First, there is considerable evidence from in vitro studies that [33H] glucose can be detritiated as a result of futile cycling between fructose-6-phosphate and fructose diphosphate (6, 7) and during recycling through the pentose phosphate pathway (8) . Second, [33H]glucose may be incorporated into and released from glycogen without losing its tritium (9) . Therefore, under conditions of rapid glycogen synthesis concurrent with or followed by glycogen breakdown (e.g., transition from the fed to the postabsorptive state), radioactive glucose will be released from glycogen along with nonradioactive glucose resulting in an underestimate of hepatic glucose production and total glucose utilization. This error will be increased if, as has been reported, most recently formed glycogen is the first to be released during glycogen breakdown (10) .
By contrast, [23H]glucose should lose its label during passage into and out of glycogen (11, 12) . However in mammals,
[23H]glucose also loses its label as part of the glucose/glucose-6-phosphate futile cycle (3, 5, 8, 13) . This results in an overestimate of glucose turnover rates in the postabsorptive state. However, in dogs the percent overestimate observed with the use of [23HIglucose is reduced when glucose flux increases during the hyperglycemia and hyperinsulinemia produced by infusion of glucose (14, 15) .
The extent of futile cycling and cycling through glycogen is dependent on the relative flux through the glycogenic, glycogenolytic, and Embden-Meyerhof pathways (16) . Because the activities of the enzymes in these pathways may be markedly different in diabetic and nondiabetic man (17, 18) , the present studies were undertaken to determine: (a) whether estimates of glucose utilization and production measured with [23H] and P33H~glucose are equivalent to those obtained with [6'4C] glucose in the postabsorptive state and during insulin-induced stimulation of glucose turnover in diabetic and nondiabetic man; (b) whether the relationships between turnover rates measured with these three isotopes are the same in both groups; and (c) whether each isotope provides an equal assessment of hepatic and extrahepatic insulin resistance.
To examine these questions, we measured glucose turnover in diabetic and nondiabetic subjects before and during infusion of insulin, using simultaneous infusions of [6'4C] Carbon dioxide produced by the decarboxylation was trapped in 0.1 ml hyamine (1 mM in methanol, J. T. Baker Chemical Co., Philipsburg, NJ) contained in a plastic well (Kontes Co., Vineland, NJ) suspended from the rubber stopper. After the 24-h incubation period, the well containing hyamine was placed in a scintillation vial along with 10 ml SafetySolve and 1 ml water, and [14C] radioactivity was counted as above. The efficiency of hyamine trapping was assessed by the external standards. Overall trapping was 62.1±1.1% (interassay coefficient of variation 9.5%, intraassay coefficient of variation 10.5%), which corrected for quench averaged 96.4±0.4%.
Calculation ofglucose utilization. Glucose utilization rates were determined for each isotope before the first insulin infusion and during the last 40 min of each subsequent infusion as described previously (19) . Glucose utilization rates were calculated by employing the non-steadystate equations of Steele (2) as modified by DeBodo (1). The pool fraction in these equations was assumed to be 0.5.
Statistics. Data in the text and figures are given as mean+SEM. Statistical analyses were performed using the paired and nonpaired twotailed t test for normally distributed data, and the Wilcoxon pairedsample and Mann-Whitney tests for nonnormally distributed data. Overall differences between turnover rates during insulin infusions both between isotopes and between diabetic and nondiabetic subjects were tested using the sum of all observations for each parameter.
Results
Plasma glucose and insulin concentrations and glucose infusion rates (Fig. 1) . Plasma glucose concentrations were greater in the diabetic patients than nondiabetic subjects (180±29 vs. 94±1 mg-dE'), P < 0.02). Plasma glucose concentrations were allowed to decrease during the first insulin infusion in the diabetic subjects until euglycemia was achieved. Thereafter, plasma glucose concentrations were maintained at 95±1 mg dl-' (mean coefficient of variation, 4.4±0.4%), which did not differ from the plasma glucose concentrations in the nondiabetic subjects (95±1 mgdl-' mean coefficient of variation 5.0±0.4%) during the insulin infusions.
Plasma-free insulin concentrations were significantly greater in the diabetic than nondiabetic subjects both before (18±7 vs.
3±1 AU-ml-', P = 0.01) and during the 0.4 mU-kg-'-min-' insulin infusion (31±7 vs. 20±1 MU-ml-', P = 0.005), and slightly but not significantly greater during the 1.0 and 2.0 mU-kg-'-min-' insulin infusions (72±12 vs. 60±4, 147±16 vs. 127±10 AU-ml-', respectively). The glucose infusion rates required to maintain euglycemia were significantly lower in the diabetic patients than the nondiabetic subjects at all insulin infusion rates (1.7±0.5 vs. 4.9±0.5 mg-kg-'-min-', P = 0.001, 5.6±0.8 vs. 9.0±0.5 mg-kg-'-min-', P = 0.004, 8.0±0.7 vs. 10.2±0.4 mgkg-'-min-', P = 0.01 mg-kg-'-min-' during the 0.4, 1.0, and 2.0 mU-kg-'-min-' insulin infusions, respectively).
Glucose turnover in the postabsorptive state. Before infusion ofinsulin, glucose turnover (glucose utilization and production) rates in the diabetic patients determined with [6'4C]glucose (3.1±0.3 mg-kg-'-min-') were significantly greater than those determined with [33Hjglucose (2.6±0.3 mg-kg-'-min-1, P = 0.007) and slightly but not significantly lower than those with Glucose turnover rates determined with [614C]glucose were significantly greater (P = 0.02) in the diabetic than nondiabetic subjects. Glucose turnover rates were also greater in the diabetic than nondiabetic subjects when determined with both [23H] and
[33H]glucose; however, these differences did not reach statistical significance (P = 0.13 and 0.16, respectively).
Glucose turnover during insulin infusion (Fig. 2) . During insulin infusion, glucose turnover rates in the diabetic patients Plasma insulin, /U *-ml-'
Comparison ofinsulin-induced glucose utilization in diabetic and nondiabetic subjects (Fig. 3) . To determine whether use of different isotopes would influence conclusions regarding the degree ofinsulin resistance in diabetes mellitus, glucose utilization rates measured with each isotope were compared in the diabetic and nondiabetic subjects. Diabetic patients would be judged to have decreased glucose utilization no matter which isotope was used (overall P = 0.004, 0.008, and 0.002 for [6 to the conclusion that glucose utilization was decreased at all insulin concentrations (P = 0.03-0.001). On the other hand, use of [33H]glucose would lead to the conclusion that glucose utilization in the diabetic subjects was significantly lower than that in the nondiabetic subjects during the 0.4 (P = 0.002) and 1.0 (P = 0.005) mU-kg-'-min-1 insulin infusions but not during the highest insulin infusion (P = 0.15).
Comparison of insulin-induced suppression of endogenous glucose production in diabetic and nondiabetic subjects (Fig. 4) . Because glucose production rates are calculated by subtracting the actual amount ofglucose being infused from the isotopically determined glucose turnover rates, differences between turnover rates determined with the three isotopes resulted in different relative patterns of suppression ofglucose production in the diabetic and nondiabetic subjects. To determine whether differences existed between diabetic and nondiabetic subjects once maximal suppression had occuffed, glucose production rates were compared during the 1.0 and 2.0 mU-kg-'-min-1 insulin infusions. Suppression determined with [614C]glucose in the nondiabetic subjects (-0.8±0. 
Discussion
Tritiated isotopes ofglucose have been used extensively to measure rates of glucose production and utilization in diabetic and nondiabetic man. Use of these isotopes assumes that their metabolism reflects the metabolism of the carbon skeleton of glucose. This assumption is based primarily on studies in postabsorptive nondiabetic animals and man (3, 5, 6, (12) (13) (14) 25 [6'4C] glucose in the diabetic patients, but were lower in the nondiabetic subjects. Both futile cycling and incorporation of radioactivity into and release from glycogen can alter isotopically determined glucose turnover rates (16) . The slightly higher glucose utilization rates observed with [23H]glucose than those with [614C]glucose in the current experiments after an overnight fast are in agreement with studies in mammals (3, 5, (11) (12) (13) and recent studies in nondiabetic man (12, 26, 27) . This overestimation of glucose utilization has been shown in animals to result from detritiation of [23H]glucose during passage from glucose-6 to fructose-6 to glucose-6-phosphate (8) . Because the glucose/glucose-6-phosphate cycle results in hydrolysis ofATP without full metabolism ofglucose, this process has been referred to as futile cycling (28).
The absolute rate ofthis cycle tended to increase with insulininduced glucose utilization, reaching a maximum during the The current experiments, however, have not excluded the possibility that glucose turnover rates determined with [6'4C]glucose were artifactually low due to uptake and release of glucose from glycogen without loss of radioactive label. This could be a particular problem if the outer layers of glycogen are selectively labeled (10) . We believe this explanation to be unlikely because the difference between turnover rates determined with [23H1 and [6'4C] glucose, if anything, increased with increasing insulin concentrations at a time when hepatic glucose release (and therefore potential release of radioactive label from glycogen) was decreasing. Overall, our results strongly support the presence ofa glucose/glucose-6-phosphate cycle in both diabetic and nondiabetic man.
A variety of in vitro studies have demonstrated that futile cycling can also occur at the fructose-6-phosphate/fructose diphosphate level (6, 7) . In vivo, this would result in an overestimate rather than an underestimate of glucose utilization measured using [33H]glucose. The lack of significant difference between glucose utilization rates in the nondiabetic subjects calculated with [33H]glucose and those calculated with [6'4C] glucose in the postabsorptive state are consistent with the previous report by Streja et al. (25) , and recent reports by Shulman et al. (26) and Argound et al. (30) . Taken together, these findings suggest that futile cycling in the postabsorptive man at the fructose-6-phosphate/fructose diphosphate level is insignificant. However, this conclusion rests on the assumption that (39, 40) . This isotope effect has been demonstrated in both muscle (39) and liver (40) . Because the mass oftritium is greater than that of deuterium, it can be calculated that tritiated dihydroxyacetone-phosphate would be metabolized at only one-third the rate of ordinary substrate (39 [23H] glucose indicated impaired suppression of hepatic glucose production in IDDM at high insulin concentrations only ifthe absolute rates were considered (i.e., negative glucose production rates retained). Ifnegative glucose production were considered as zero, then [33H]glucose also would lead to the conclusion that suppression of glucose production was equivalent at high insulin concentrations in the diabetic and nondiabetic subjects.
It should be noted that the differences in the pattern of suppression ofglucose production at submaximal and maximal insulin concentrations using the three different isotopes were due to differences in the perceived suppression in the nondiabetic rather than the diabetic patients. This stemmed from the fact that [33Hjglucose underestimated actual turnover in the nondiabetic patients. Using [614C]glucose as the standard, the current studies indicate that diabetic patients have hepatic as well as extrahepatic insulin resistance. Even this conclusion must be qualified by the possibility that there was greater incorporation into and release of [614C]glucose from glycogen in the nondiabetic patients than in the diabetic patients. Because this label does not lose its label during passage through glycogen, incorporation into and release from glycogen would lead to an underestimate of glucose production with apparent greater suppression in the nondiabetic subjects. This possibility seems unlikely, however, because it would imply greater activity of glycogen phosphorylase in the nondiabetic subjects than in the diabetic patients, the opposite of what has been demonstrated in vitro (17) .
In summary, the current studies indicate that similar estimates of glucose turnover were obtained using [6'4C] 
